Pre-Open Stock Movers 02/26: (HTZ) (EVER) (MNK) Higher; (AMR) (CAT) (TSLA) Lower (more...)

February 26, 2019 9:23 AM EST

Get inside Wall Street with StreetInsider Premium. Claim your 1-week free trial here.

Today's Pre-Open Movers

Alta Mesa Resources (NASDAQ: AMR) 44.1% LOWER; Announces initial 2019 outlook and preliminary Q4 results. Guggenheim downgraded from Buy to Sell.

Heat Biologics (NASDAQ: HTBX) 25.2% HIGHER; disclosed that in connection with the planned oral presentation of the company's new HS-110 interim Phase 2 data at the upcoming 2019 ASCO-SITC Clinical Immuno-Oncology Symposium on February 28, 2019, by the principal investigator for the trial, Daniel Morgensztern, MD, Associate Professor of Medicine and Director of Thoracic Oncology, Washington University School of Medicine, an abstract has been posted on the ASCO-SITC website.

VistaGen Therapeutics (NASDAQ: VTGN) 19.9% LOWER; announced the pricing of its underwritten public offering of 10,000,000 shares of its common stock at a public offering price of $1.00 per share

Zynerba Pharmaceuticals, Inc. (NASDAQ: ZYNE) 17.5% HIGHER; announced that the U.S. Patent and Trademark Office has issued US Patent No. 10,213,390, titled “Treatment of Fragile X Syndrome with Cannabidiol” which includes claims directed to methods of treating Fragile X Syndrome by administering a therapeutically effective amount of synthetic or purified cannabidiol.

Neovasc Inc. (NASDAQ: NVCN) 17.5% LOWER; announced today that it has commenced a proposed underwritten public offering (the "Offering") of common shares of the Company.

Hertz Global (NYSE: HTZ) 16.1% HIGHER; reported Q4 EPS of ($0.55), $0.35 better than the analyst estimate of ($0.90). Revenue for the quarter came in at $2.3 billion versus the consensus estimate of $2.15 billion.

EverQuote (NASDAQ: EVER) 15.5% HIGHER; reported Q4 EPS of ($0.28), $0.01 better than the analyst estimate of ($0.29). Revenue for the quarter came in at $39.8 million versus the consensus estimate of $38.03 million. EverQuote sees Q1 2019 revenue of $47-49 million, versus the consensus of $47.95 million. BofA/Merrill Lynch upgraded EverQuote from Neutral to Buy with a price target of $10.50.

Ferroglobe (NASDAQ: GSM) 14.6% HIGHER; reported Q4 EPS of ($0.05), in-line with the analyst estimate of ($0.05). Revenue for the quarter came in at $603.5 million versus the consensus estimate of $486.22 million.

Mallinckrodt (NYSE: MNK) 13.5% HIGHER; reported Q4 EPS of $2.18, $0.26 better than the analyst estimate of $1.92. Revenue for the quarter came in at $834.9 million versus the consensus estimate of $636.61 million. Mallinckrodt sees FY2019 EPS of $8.10-$8.40, versus the consensus of $7.37.

Dillard's (NYSE: DDS) 12.8% HIGHER; reported Q4 EPS of $3.22, $0.46 better than the analyst estimate of $2.76. Revenue for the quarter came in at $2.06 million versus the consensus estimate of $2.08 million. Based upon comparable 13-week periods ended February 2, 2019 and February 3, 2018, total merchandise sales increased 1% and sales in comparable stores increased 2%.

Tenet Healthcare (NYSE: THC) 12.1% HIGHER; reported Q4 EPS of $0.51, $0.23 better than the analyst estimate of $0.28. Revenue for the quarter came in at $4.62 billion versus the consensus estimate of $4.51 billion. Tenet Healthcare sees FY2019 EPS of $2.08-$2.59, versus the consensus of $1.94. Tenet Healthcare sees FY2019 revenue of $18-18.4 billion, versus the consensus of $18.06 billion. Tenet Healthcare sees Q1 2019 EPS of $0.10-$0.43, versus the consensus of $0.41. Tenet Healthcare sees Q1 2019 revenue of $4.3-4.6 billion, versus the consensus of $4.53 billion.

Medpace Holdings (NASDAQ: MEDP) 10.7% LOWER; reported Q4 EPS of $0.75, $0.08 better than the analyst estimate of $0.67. Revenue for the quarter came in at $192.1 million versus the consensus estimate of $184.96 million. Medpace Holdings sees FY2019 EPS of $2.58-$2.69, versus the consensus of $2.92. Medpace Holdings sees FY2019 revenue of $783-807 million, versus the consensus of $799.2 million.

AutoZone (NYSE: AZO) 9.8% HIGHER; reported Q2 EPS of $11.49, $1.53 better than the analyst estimate of $9.96. Revenue for the quarter came in at $2.5 billion versus the consensus estimate of $2.45 billion. Domestic same store sales, or sales for stores open at least one year, increased 2.6% for the quarter.

Immunomedics (NASDAQ: IMMU) 7.8% LOWER; reported Q2 EPS of ($0.84), $0.50 worse than the analyst estimate of ($0.34). Michael Pehl has stepped down from the role of President, CEO and member of the Board, due to personal reasons.

2u (NASDAQ: TWOU) 7.5% HIGHER; reported Q4 EPS of $0.23, $0.02 better than the analyst estimate of $0.21. Revenue for the quarter came in at $155.1 million versus the consensus estimate of $114.85 million. 2u sees Q1 2019 EPS of ($0.19)-($0.18), versus the consensus of ($0.21). 2u sees Q1 2019 revenue of $121.5-1 22.1 million, versus the consensus of $121.7 million. 2u sees FY2019 EPS of ($0.37)-$0.33, versus the consensus of ($0.37). 2u sees FY2019 revenue of $546.6-550.8 million, versus the consensus of $547.06 million.

Etsy (NASDAQ: ETSY) 6.2% HIGHER; reported Q4 EPS of $0.32, $0.11 better than the analyst estimate of $0.21. Revenue for the quarter came in at $200 million versus the consensus estimate of $194.89 million. Etsy sees FY2019 revenue of $779-797 million, versus the consensus of $776.2 million. Adjusted EBITDA Margin* 23-25% ~$181M - $197M.

RealPage (NASDAQ: RP) 5.5% LOWER; reported Q4 EPS of $0.39, $0.01 better than the analyst estimate of $0.38. Revenue for the quarter came in at $227 million versus the consensus estimate of $229.09 million. RealPage sees Q1 2019 EPS of $0.39-$0.41, versus the consensus of $0.41. RealPage sees Q1 2019 revenue of $232.8-234.8 million, versus the consensus of $237.36 million. RealPage sees FY2019 EPS of $1.70-$1.79, versus the consensus of $1.76. RealPage sees FY2019 revenue of $980-1000 million, versus the consensus of $974 million.

Kadmon Holdings (NYSE: KDMN) 5.3% HIGHER; Citi upgraded from Neutral to Buy with a price target of $4.00 (from $2.82).

Sage Therapeutics (NASDAQ: SAGE) 5.2% LOWER; announced that it has commenced an underwritten public offering of $500,000,000 of its common stock. Sage also intends to grant the underwriters a 30-day option to purchase up to an additional $75,000,000 of its common stock offered in the public offering. All shares in the offering are to be sold by Sage.

Rent-A-Center (NASDAQ: RCII) 5.2% HIGHER; reported Q4 EPS of $0.35, $0.15 better than the analyst estimate of $0.20. Revenue for the quarter came in at $661.75 million versus the consensus estimate of $656.78 million. Rent-A-Center sees FY2019 EPS of $1.75-$2.15, versus the consensus of $1.77. Rent-A-Center sees FY2019 revenue of $2.585-2.63 billion, versus the consensus of $2.62 billion.

Corcept Therapeutics (NASDAQ: CORT) 4.4% HIGHER; reported Q4 EPS of $0.18, $0.03 better than the analyst estimate of $0.15. Revenue for the quarter came in at $66.8 million versus the consensus estimate of $69.61 million. Corcept Therapeutics sees FY2019 revenue of $285-315 million, versus the consensus of $298.3 million.

Intelsat S.A (NYSE: I) 3.9% HIGHER; Evercore ISI initiates coverage with a Outperform rating and a price target of $50.00.

Caterpillar (NYSE: CAT) 3.7% LOWER; UBS double downgraded from Buy to Sell with a price target of $125.00 (from $154.00) as they expect 2020 EPS to decline.

Tesla (NASDAQ: TSLA) 2.7% LOWER; SEC is pursuing a contempt order against CEO Elon Musk, saying he violated a fraud settlement by tweeting material information without preapproval.



Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In





Related Categories

Special Reports

Related Entities

UBS, Citi, Tesla, S1, Pre-Open Losers, Pre-Open Winners, Pre Market Movers, Guggenheim, BofA/Merrill Lynch